nivolumab,ipilimumab
bms
['nivo', 'niche-2']
the niche-2-trial asessing the safety, feasibility &amp; 3 yr survival of neodjuvinant nivo + ipu results were presented by . unprecedented major pathologic responses in 95% of patients with dmmr, will be practice changing in the clinic. amazing results! #esmo22 
Oncode Institute is an independent institute dedicated to understanding cancer and translating research into practice more efficiently.